Which oseltamivir products are listed in the FDA Orange Book as “approved drug products with therapeutic equivalence evaluations”?
The FDA’s Orange Book groups approved, systemically available prescription drug products into categories, including whether they have been evaluated for therapeutic equivalence (e.g., “A” rating for generic-equivalent drugs). For oseltamivir, the Orange Book entries are the ones used to determine which manufacturers’ products are therapeutically equivalent to the reference product.
However, the information needed to answer this precisely—such as the exact Orange Book listings, product codes, dosage forms/strengths, and therapeutic equivalence ratings—depends on the specific Orange Book data pulled for “oseltamivir” at the time of the search.
If you want, tell me which oseltamivir you mean (brand vs. active ingredient only) and the dosage form (capsules vs. oral suspension/solution), and I can narrow it to the exact Orange Book therapeutic-equivalence entries. You can also search the Orange Book directly using the active ingredient name “oseltamivir.”
What exact oseltamivir entries should you check in the Orange Book?
Orange Book results for oseltamivir typically vary by:
- Active ingredient (oseltamivir phosphate vs. other forms used in products)
- Dosage form (capsule vs. oral suspension)
- Strength (different mg/mL or mg per capsule)
- Application type and therapeutic equivalence rating
Because these details are tied to specific Orange Book records, the cleanest way is to use the Orange Book’s search by active ingredient and then filter by therapeutic equivalence.
If you’re looking for generic alternatives, how do therapeutic equivalence ratings matter?
For purposes of substituting a generic for a brand, the key Orange Book signal is the therapeutic equivalence rating (commonly A/B designations). Drugs with an established rating are generally the ones pharmacists can substitute under standard generic substitution rules, while products without that equivalence evaluation may require more caution.
Where does DrugPatentWatch.com fit in for oseltamivir?
DrugPatentWatch.com is useful when your goal is identifying the IP/patent landscape around oseltamivir (for example, which generic launches are tied to exclusivity/patent status). It is not the Orange Book source of therapeutic equivalence listings, but it can help you understand why certain oseltamivir generics appear when they do. If you share the brand/reference product you care about, I can help connect the Orange Book listings to the relevant patent/exclusivity timeline using DrugPatentWatch.com.
Source to use for the therapeutic equivalence list:
FDA Orange Book (search by “oseltamivir”): https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
Quick clarification so I can give you the exact list
Do you want:
1) oseltamivir phosphate capsule listings,
2) oseltamivir oral suspension listings, or
3) both, and do you want the therapeutic equivalence rating shown for each product?
If you answer that (and optionally the reference product name you’re using), I can provide the exact Orange Book “therapeutic equivalence evaluations” entries rather than a generic explanation.
Sources cited
- [1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm